Peripheral NLRP3 Inhibitor Speeds Diabetic Ulcer Healing
ISM5059 - our peripherally restricted NLRP3 inhibitor - accelerates diabetic foot ulcer healing. Oral presentation at ADA 2026. No CNS exposure. Clean safety profile for a chronic wound indication where you need to resolve inflammation without systemic immunosuppression. https://t.co/vNCHxVfNbr
Metformin Restores NCoR1, Delays Primate Gut Aging
The aging gut, mapped at single-cell resolution in primates. NCoR1 decline = barrier failure + chronic inflammation + stem cell lineage shift away from absorptive cells. Metformin restores NCoR1 and delays intestinal aging in NHPs. Li et al., Nature Aging 2026 https://t.co/OLdXp99EiG
PKMYT1 Emerges as Top Synthetic‑Lethal Oncology Target
PKMYT1 went from niche cell-cycle kinase to one of oncology's hottest synthetic-lethal targets in 4 years - 5 candidates now in the clinic. Our new patent review (2021-2025) maps the inhibitor + degrader landscape. PoC established by RP-6306 in CCNE1/FBXW7-altered cancers. https://t.co/SOUmgeOkEq
Unfiltered's 2026 Longevity Top 100 Ranked
Who runs longevity in 2026? Unfiltered published their top 100 list. Here is the digest with my comments https://t.co/a0hFUmaHZ8 https://t.co/BrcOym0TbT
Human Longevity Launches AI Foundation Models with Insil
Thank you Ben Adams and Fierce Biotech for covering Human Longevity's launch of Human Life Foundation Models and the Insilico Medicine collaboration on AI-powered longevity research. https://t.co/iCQbiRKrwc https://t.co/jmOBNHksyX
AI‑Designed MOFs Validated for Carbon Capture
Important preprint with @aramco: Sanity Pipeline for AI-generated MOFs. Validated materials matter for direct air capture, carbon management, sustainability, and decarbonizing the world. cc @PeterDiamandis https://t.co/t61NFwbARH
Money, Patience, Intent—And Animal Models Drive Drug Discovery
After we showed that we can discover a drug in the UAE from scratch, many countries and their R&D organizations started reaching out with the offers "set up a site in our country and gain access to our wonderful population...
Ultra‑novel Drugs Needed to Add Years of Health
It was a great pleasure to speak with @business live during the JP Morgan conference. Check out the latest on AI R&D productivity, #MMAIGym, and, most importantly dual-purpose aging and longevity therapeutics. Longevity should be our common purpose -...
AI Transforming Longevity and Drug Discovery at BIO2026
I will be at BIO #BIO2026 speaking on AI for longevity and AI for drug discovery https://t.co/hgLiNih8r1 https://t.co/JAG41qB4jQ
Sponsoring Caltech Longevity Hackathon Highlights AI for Longevity
Very happy to sponsor the Caltech Longevity Hackathon focused on AI for longevity organized by @AndreaVOls who also founded the @cit_longevity Club . Caltech Students are the future of tech. These are the people who know how...
Up City: AI‑Driven Megaproject Merges Tech, Health, Longevity
In the world of AI, the main success factors will be capital, infrastructure, ideas and the amount of life you have left. This new Technology and Biotechnology focused TOD megaproject called Up City (formerly Top Town) SuperDNA you will...
Longevity Biotech Matures: Precise Indication‑Focused Drug Development
The longevity biotechnology field is coming of age in the best possible way. A recent analysis captures how the sector has learned to speak pharma’s language fluently—moving from broad claims about “slowing aging” to precise, indication-focused drug development with conventional endpoints,...
AI Amplifies Human Strengths, Not Replaces Jobs
Don't get the wrong idea from the picture - I am only Open to Work harder at Insilico to increase your lifespan and peakspan. Just picked up "Open to Work: How to Get Ahead in the Age of AI" by...
AI-Driven Anti‑Aging Pipeline Leads Pharma, Yet Remains Niche
I just found an old T-shirt from 2016 with my one true mission. Since then, we took the lead in AI drug discovery in general and pharma is still a bit cold when it comes to aging so we had...
New GLP‑1 Scale Target Tackles Aging Inflammation
Love what Kristen at BioAGE is doing (see the link to Fierce Pharma by Will Maddox in the comments). We also have a portfolio of BIC NLRP3 in Phase I and IND-enabling. Love this target with all my heart and...